![PFE vs MRNA: Pfizer Inc. vs Moderna, Inc. Stock Comparison [2026]](https://images.unsplash.com/photo-1611974789855-9c2a0a7236a3?auto=format&fit=crop&w=1600&q=80)
A head-to-head, data-driven comparison of PFE (Pfizer Inc.) and MRNA (Moderna, Inc.) — covering valuation, growth, dividends, risk, and which one fits your portfolio. All metrics pulled from live market data.
If you're choosing between PFE and MRNA, the answer depends on what kind of investor you are. Both are watched closely in the Healthcare sector, but they look different on almost every metric that matters: P/E, growth rate, dividend, balance-sheet quality, and volatility.
Below we break down the head-to-head numbers, name a winner on each dimension, and give a clear recommendation by investor type. Want to run this comparison live with charts and 50+ metrics? Use the free interactive PFE vs MRNA comparison tool.
Pfizer Inc. (PFE)
Healthcare · Drug Manufacturers - General · NYSE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The c…
Moderna, Inc. (MRNA)
Healthcare · Biotechnology · NASDAQ
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of …
Quick Verdict
How to Read This PFE vs MRNA Comparison
Stock comparisons can be misleading if you focus on a single metric. A "cheaper" P/E doesn't automatically make a stock a better buy — slower-growing companies should trade at lower multiples. The right framework is to score each name on four independent dimensions and weight them according to your investing goal.
The Four-Dimension Framework
- Growth — How fast is the business expanding? We look at year-over-year revenue and EPS growth. Faster growers earn premium multiples but carry execution risk.
- Value — Are you paying a fair price? P/E, P/B, EV/EBITDA, and free cash flow yield tell you what the market is charging per dollar of business performance.
- Income — Does the stock pay you to wait? Dividend yield, payout ratio, and dividend history matter for retirees, FIRE investors, and anyone funding ongoing expenses.
- Safety — How much can you lose if things go wrong? Low beta, manageable debt-to-equity, and high ROE indicate a more durable business.
No single stock wins on all four. PFE and MRNA likely each lead on at least one dimension. The "right" answer is the one that matches your portfolio gap — if you already own a basket of high-growth tech, the cheaper, lower-volatility name probably adds more diversification value than another momentum bet.
Side-by-Side Metrics: PFE vs MRNA
| Metric | PFE | MRNA |
|---|---|---|
| Price | $25.61 | $48.79 |
| Market Cap | $145.61B | $19.35B |
| P/E Ratio (lower is cheaper) | 0.00 | 0.00 |
| EPS | $0.00 | $0.00 |
| Dividend Yield | 6.91% | 0.00% |
| Beta (volatility vs market) | 0.41 | 1.06 |
| ROE (higher is better) | 0.00% | 0.00% |
| Debt/Equity (lower is safer) | 0.00 | 0.00 |
| Revenue Growth (YoY) | -1.65% | -39.23% |
| EPS Growth (YoY) | -4.23% | 21.68% |
| 52-Week High | $27.69 | $59.55 |
| 52-Week Low | $20.92 | $22.28 |
| Sector | Healthcare | Healthcare |
Which Stock Has Better Growth?
PFE grew revenue -1.65% and EPS -4.23% year-over-year. MRNA grew revenue -39.23% and EPS 21.68%.
PFE wins — revenue -1.65% and EPS -4.23% YoY outpace the other name.
Which Stock Is Cheaper on Valuation?
PFE trades at a P/E of 0.00, while MRNA trades at 0.00. ROE for PFE is 0.00% versus 0.00% for MRNA.
Roughly tied — both trade at similar earnings multiples.
Which Stock Pays More Income?
PFE yields 6.91%; MRNA yields 0.00%.
PFE wins — 6.91% yield vs the other name's lower payout.
Which Stock Is the Safer Bet?
PFE has a beta of 0.41 and a debt-to-equity ratio of 0.00. MRNA sits at beta 1.06 and D/E 0.00.
PFE wins — beta 0.41 and D/E 0.00 make it the more defensive name.
Where PFE and MRNA Sit in Their 52-Week Range
Price action over the last 12 months gives important context. A stock near its 52-week high has momentum on its side but limited room before profit-taking; one near its low may be a value opportunity or a structural problem.
- PFE currently trades at $25.61, in the upper half of its 52-week range — established uptrend with room to run if fundamentals continue (52-week range: $20.92–$27.69).
- MRNA currently trades at $48.79, in the upper half of its 52-week range — established uptrend with room to run if fundamentals continue (52-week range: $22.28–$59.55).
Key Risks for PFE and MRNA
Every stock has tail risks that the headline numbers don't capture. Here's what stands out from the available metrics:
- PFE: low beta of 0.41 dampens both upside and downside vs. the broader market; yield of 6.91% above 6% deserves payout-ratio scrutiny; revenue declined 1.65% year-over-year — confirm whether this is cyclical or structural.
- MRNA: revenue declined 39.23% year-over-year — confirm whether this is cyclical or structural.
This is a quick heuristic risk scan, not a full risk assessment. Always read the "Risk Factors" section of each company's most recent 10-K filing before investing.
PFE vs MRNA — Best Pick by Investor Type
- Long-term holder (10+ years): Lean toward PFE; durability and balance-sheet strength matter more than the next-quarter print.
- Income / dividend-focused: PFE — higher yield, but always check payout sustainability before chasing.
- Aggressive growth: PFE — faster top-line and EPS expansion at the cost of richer multiples.
- Value-oriented: either name works — paying less per dollar of earnings, with the trade-off of slower growth.
The Bottom Line: PFE vs MRNA
On balance, PFE wins on 3 of 4 dimensions, making it the slightly better all-around pick for a generalist investor.
If you're the kind of investor who hates picking, the easiest answer is to own both names in equal weight inside a sector basket and rebalance once a year. That way, you capture the winner without having to predict it, and you pay the lowest possible behavioral cost (no second-guessing, no FOMO).
If you must pick one, anchor on the dimension that fixes your biggest portfolio gap — not the one with the most exciting headline. Tilting toward defensive names when you already own three growth winners adds more risk-adjusted return than another momentum bet.
Metrics Glossary — What Each Number Means
If you're new to fundamental analysis, here's a plain-English reference for every metric in the table above:
- P/E Ratio (Price-to-Earnings): Share price divided by earnings per share. Tells you how many years of current earnings the stock costs. Lower = cheaper, but slow growers should have lower P/Es.
- EPS (Earnings Per Share): Net income divided by shares outstanding. The per-share slice of company profits.
- Market Cap: Share price × shares outstanding. The market's total valuation of the company's equity.
- Dividend Yield: Annual dividend per share ÷ current price, expressed as a percent. A 3% yield means you receive $3 per year for every $100 invested at today's price.
- Beta: Volatility relative to the broader market (S&P 500 = 1.0). Beta of 1.5 means the stock historically moves 1.5× the market, both up and down.
- ROE (Return on Equity): Net income ÷ shareholder equity. How efficiently the company turns equity capital into profit. Above 15% is generally considered high quality.
- Debt-to-Equity: Total debt ÷ shareholder equity. Lower ratios mean less leverage and lower interest-rate risk.
- Revenue Growth (YoY): Percentage change in revenue versus the year-ago period. The single best top-line health check.
- EPS Growth (YoY): Same comparison but for earnings per share — captures both revenue growth and operating leverage.
- 52-Week High / Low: The trailing 12-month price range. Useful for context on current price (e.g. a stock near its 52-week high is in an uptrend; near the low is in a downtrend or value zone).
Run a Live PFE vs MRNA Comparison
The numbers above reflect the latest available data, but markets move every minute. For a real-time, interactive head-to-head with price charts (1D to YTD), all 50+ metrics, and AI-powered insights, use our free tool — it's free, no signup required, and shareable:
Related Stock Comparisons
Continue your research with these head-to-head comparisons involving PFE or MRNA:
Frequently Asked Questions: Is PFE
Disclaimer: This comparison is generated from live market data for informational purposes only. It is not investment advice, a recommendation to buy or sell any security, or a substitute for the analysis of a licensed financial advisor. Past performance is not indicative of future results. Always read the most recent 10-K and consult a qualified professional before making investment decisions. StockSignal24 is not responsible for losses incurred from trading decisions made based on this content.